Coravog-R0.2/1 - Manufacturers & Suppliers - Third Party Contract Manufacturing - PCD Pharma Franchise
Repaglinide + Voglibose is a combination of two antidiabetic medicines: Repaglinide and voglibose. Repaglinide is a meglitinide analogue which increases the amount of insulin released by the pancreas. Voglibose is an alpha-glucosidase inhibitor which inhibits the intestinal enzymes that cause breakdown of complex sugars into simple sugars such as glucose.
REPAGLINIDE+VOGLIBOSE is composed of two medicines, namely Repaglinide and voglibose. Repaglinide increases the amount of insulin released by the pancreas by stimulating the pancreas to release insulin to your body and helps regulate the amount of glucose (sugar) in the blood. Voglibose helps control the amount of glucose (sugars) in the blood by inhibiting the intestinal enzyme (alpha-glucosidase) and delaying the digestion and absorption of carbohydrates in the intestine. Altogether, they prevent blood sugar from rising very high after meals.
Drug-Drug Interactions: REPAGLINIDE+VOGLIBOSE interacts with Beta-blocker medications (e.g. metoprolol), Antidiabetic class of medications (e.g. metformin, insulin, sitagliptin, empagliflozin), and pain killers (e.g. aspirin). And also, inform all your medical conditions, ongoing therapies to your doctor before prescribing this medication. By considering these, your doctor may check the drug interactions before prescribing this medication.
Drug-Food Interactions: Intake of excessive alcoholic beverages may increase the chance of a life-threatening condition known as Lactic Acidosis. So, avoid intake of alcoholic beverages with REPAGLINIDE+VOGLIBOSE.
Drug-Disease Interactions: Caution should be exercised with the people affected with Type I diabetes, cardiovascular disorders, hypoglycaemia, liver disease, renal impairment.